Page 139 - Read Online

Chan et al. J Transl Genet Genom 2024;8:13-34 https://dx.doi.org/10.20517/jtgg.2023.36 Page 133

J Med 2008;359:1577-89. DOI PubMed
60. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
N Engl J Med 2005;353:2643-53. DOI PubMed PMC
61. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for
prediction of insulin requirement in type 2 diabetes. UK prospective diabetes study group. Lancet 1997;350:1288-93. DOI
62. Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat
Rev Endocrinol 2017;13:674-86. DOI PubMed
63. Medici F, Hawa M, Ianari A, Pyke DA, Leslie RD. Concordance rate for type II diabetes mellitus in monozygotic twins: actuarial
analysis. Diabetologia 1999;42:146-50. DOI PubMed
64. Zhang J, Yang Z, Xiao J, et al; China National Diabetes and Metabolic Disorders Study Group. Association between family history
risk categories and prevalence of diabetes in Chinese population. PLoS One 2015;10:e0117044. DOI PubMed PMC
65. Li JK, Ng MC, So WY, et al. Phenotypic and genetic clustering of diabetes and metabolic syndrome in Chinese families with type 2
diabetes mellitus. Diabetes Metab Res Rev 2006;22:46-52. DOI
66. Zhang Y, Luk AOY, Chow E, et al. High risk of conversion to diabetes in first-degree relatives of individuals with young-onset type
2 diabetes: a 12-year follow-up analysis. Diabet Med 2017;34:1701-9. DOI
67. Bonnefond A, Unnikrishnan R, Doria A, et al. Monogenic diabetes. Nat Rev Dis Primers 2023;9:12. DOI
68. Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med 1974;43:339-57. DOI PubMed
69. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N
Engl J Med 2001;345:971-80. DOI PubMed
70. Feingold K. Atypical forms of diabetes. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth:
MDText.com, Inc.; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279128/ [Last accessed on 15 Jan 2024].
71. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40. DOI
72. Todd JN, Kleinberger JW, Zhang H, et al. Monogenic diabetes in youth with presumed type 2 diabetes: results from the progress in
diabetes genetics in youth (ProDiGY) collaboration. Diabetes Care 2021;44:2312-9. DOI PubMed PMC
73. Shields BM, Shepherd M, Hudson M, et al; UNITED study team. Population-based assessment of a biomarker-based screening
pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care 2017;40:1017-25. DOI PubMed PMC
74. Christensen AS, Hædersdal S, Støy J, et al. Efficacy and safety of glimepiride with or without linagliptin treatment in patients with
hnf1a diabetes (maturity-onset diabetes of the young type 3): a randomized, double-blinded, placebo-controlled, crossover trial
(GLIMLINA). Diabetes Care 2020;43:2025-33. DOI PubMed PMC
75. Thewjitcharoen Y, Nakasatien S, Tsoi TF, Lim CKP, Himathongkam T, Chan JCN. Hypertriglyceridemia as a main feature
associated with 17q12 deletion syndrome-related hepatocyte nuclear factor 1β-maturity-onset diabetes of the young. Endocrinol
Diabetes Metab Case Rep 2022;2022:22-0297. DOI PubMed PMC
76. Thewjitcharoen Y, Wanothayaroj E, Krittiyawong S, et al. Phenotypic and genetic heterogeneity in a thai glucokinase MODY family
reveals the complexity of young-onset diabetes. Front Endocrinol 2021;12:690343. DOI PubMed PMC
77. Ng MC, Li JK, So WY, et al. Nature or nurture: an insightful illustration from a Chinese family with hepatocyte nuclear factor-1
alpha diabetes (MODY3). Diabetologia 2000;43:816-8. DOI PubMed
78. Matschinsky FM. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 2002;51 Suppl 3:S394-404.
DOI PubMed
79. Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia 2017;60:769-77. DOI
80. Yabe D, Seino Y. Type 2 diabetes via β-cell dysfunction in east Asian people. Lancet Diabetes Endocrinol 2016;4:2-3. DOI
PubMed
81. Fan Y, Fan B, Lau ESH, et al. Comparison of beta-cell function between Hong Kong Chinese with young-onset type 2 diabetes and
late-onset type 2 diabetes. Diabetes Res Clin Pract 2023;205:110954. DOI
82. López Tinoco C, Sánchez Lechuga B, Bacon S, et al. Evaluation of pregnancy outcomes in women with GCK-MODY. Diabet Med
2021;38:e14488. DOI
83. Dickens LT, Letourneau LR, Sanyoura M, Greeley SAW, Philipson LH, Naylor RN. Management and pregnancy outcomes of
women with GCK-MODY enrolled in the US Monogenic Diabetes Registry. Acta Diabetol 2019;56:405-11. DOI PubMed PMC
84. Zhu D, Gan S, Liu Y, et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-
blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol 2018;6:627-36. DOI
85. Chow E, Wang K, Lim CKP, et al. Dorzagliatin, a dual-acting glucokinase activator, increases insulin secretion and glucose
sensitivity in glucokinase maturity-onset diabetes of the young and recent-onset type 2 diabetes. Diabetes 2023;72:299-308. DOI
PubMed PMC
86. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk
equivalent to monogenic mutations. Nat Genet 2018;50:1219-24. DOI PubMed PMC
87. Wang K, Shi M, Yang A, et al. GCKR and GCK polymorphisms are associated with increased risk of end-stage kidney disease in
Chinese patients with type 2 diabetes: the Hong Kong Diabetes Register (1995-2019). Diabetes Res Clin Pract 2022;193:110118.
DOI
88. Wang K, Shi M, Huang C, et al. Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian
randomisation analysis. Cardiovasc Diabetol 2022;21:192. DOI PubMed PMC